PURPOSE: B cells participate in diverse retinal immunopathologies. Endothelial adhesion molecules and chemokines direct leukocyte trafficking. We examined the involvement of three molecular signals in retinal transendothelial migration of human B cells: ICAM-1, VCAM-1, and CXCL13. METHODS: Peripheral blood B cells were isolated by negative selection. Migration was studied in transwells populated with human retinal endothelial monolayers, using antibody to block ICAM-1 or VCAM-1. Retinal expression of CXCL13 was investigated. RESULTS: B cells crossed retinal endothelium. ICAM-1 blockade significantly reduced migration when results for all subjects were combined, and for a majority when results were analyzed by individual. This effect was irrespective of the presence or absence of CXCL13, although CXCL13 increased migration. CXCL13 was detected in neural retina and retinal pigment epithelium. Endothelial cells of some retinal vessels presented CXCL13 protein. CONCLUSION: ICAM-1 blockade may be an effective treatment in some patients with retinal diseases that involve B cells.
PURPOSE: B cells participate in diverse retinal immunopathologies. Endothelial adhesion molecules and chemokines direct leukocyte trafficking. We examined the involvement of three molecular signals in retinal transendothelial migration of human B cells: ICAM-1, VCAM-1, and CXCL13. METHODS: Peripheral blood B cells were isolated by negative selection. Migration was studied in transwells populated with human retinal endothelial monolayers, using antibody to block ICAM-1 or VCAM-1. Retinal expression of CXCL13 was investigated. RESULTS: B cells crossed retinal endothelium. ICAM-1 blockade significantly reduced migration when results for all subjects were combined, and for a majority when results were analyzed by individual. This effect was irrespective of the presence or absence of CXCL13, although CXCL13 increased migration. CXCL13 was detected in neural retina and retinal pigment epithelium. Endothelial cells of some retinal vessels presented CXCL13 protein. CONCLUSION:ICAM-1 blockade may be an effective treatment in some patients with retinal diseases that involve B cells.
Authors: Christian Loeffler; Klaus Dietz; Ariane Schleich; Holger Schlaszus; Manuel Stoll; Richard Meyermann; Michel Mittelbronn Journal: Neuropathology Date: 2010-11-24 Impact factor: 1.906
Authors: Anneclaire J De Roos; Dana K Mirick; Kerstin L Edlefsen; Andrea Z LaCroix; Kenneth J Kopecky; Margaret M Madeleine; Larry Magpantay; Otoniel Martínez-Maza Journal: Cancer Res Date: 2012-07-30 Impact factor: 12.701
Authors: Daniel J Nolan; Michael Ginsberg; Edo Israely; Brisa Palikuqi; Michael G Poulos; Daylon James; Bi-Sen Ding; William Schachterle; Ying Liu; Zev Rosenwaks; Jason M Butler; Jenny Xiang; Arash Rafii; Koji Shido; Sina Y Rabbany; Olivier Elemento; Shahin Rafii Journal: Dev Cell Date: 2013-07-18 Impact factor: 12.270
Authors: Tracy J Yuen; Kory R Johnson; Veronique E Miron; Chao Zhao; Jacqueline Quandt; Marie C Harrisingh; Matthew Swire; Anna Williams; Henry F McFarland; Robin J M Franklin; Charles Ffrench-Constant Journal: Brain Date: 2013-03-21 Impact factor: 13.501
Authors: Feargal J Ryan; Yuefang Ma; Liam M Ashander; Michael Kvopka; Binoy Appukuttan; David J Lynn; Justine R Smith Journal: Transl Vis Sci Technol Date: 2022-08-01 Impact factor: 3.048